In these B-cell NHLs with MYD88L265P mutation and even those without, BTK inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have shown efficacy by virtue of inhibiting BTK’s key role in in BCR and TLR signaling (31–37). The gene discussed is BCR; the disease is B-cell non-Hodgkin lymphoma.